Madeline Kavanagh
Universitair docent
- Naam
- Dr. M.E. Kavanagh
- Telefoon
- +31 71 527 3527
- m.e.kavanagh@lic.leidenuniv.nl
- ORCID iD
- 0000-0002-4735-1559
Meer informatie is beschikbaar op de Engelse profielpagina.
Promovendi
Universitair docent
- Wiskunde en Natuurwetenschappen
- Leiden Institute of Chemistry
- LIC/Chemical Biology
- LIC/CB/Molecular Physiology
- Katariya M.M., Snee M., Tunnicliffe R.B., Kavanagh M.E., Boshoff H.I.M., Amadi C.N., Levy C.W., Munro A.W., Abell C., Leys D., Coyne A.G. & McLean K.J. (2023), Structure based discovery of inhibitors of CYP125 and CYP142 from Mycobacterium tuberculosis, Chemistry: a European Journal 29(29): e202203868.
- Frederickson M., Selvam I.R., Evangelopoulos D., McLean K.J., Katariya M.M., Tunnicliffe R.B., Campbell B., Kavanagh M.E., Charoensutthivarakul S., Blankley R.T., Levy C.W., de Carvalho L.P.S., Leys D., Munro A.W., Coyne A.G. & Abell C. (2022), A new strategy for hit generation: novel in cellulo active inhibitors of CYP121A1 from Mycobacterium tuberculosis via a combined X-ray crystallographic and phenotypic screening approach (XP screen), European Journal of Medicinal Chemistry 230: 114105.
- Kavanagh M.E., Horning B.D., Khattri R., Roy N., Lu J.P., Whitby L.R., Ye E., Brannon J.C., Parker A., Chick J.M., Eissler C.L., Wong A.P., Rodriguez J.L., Rodiles S., Masuda K., Teijaro J.R., Simon G.M., Patricelli M.P. & Cravatt B.F. (2022), Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine, Nature Chemical Biology 18(12): 1388-1398.
- Brem J., Panduwawala T., Hansen J.U., Hewitt J., Liepins E., Donets P., Espina L., Farley A.J.M., Shubin K., Campillos G.G., Kiuru P., Shishodia S., Krahn D., Lesniak R.K., Schmidt (A.) J., Calvopina K., Turrientes M.-C., Kavanagh M.E., Lubriks D., Hinchliffe P., Langley G.W., Aboklaish A.F., Eneroth A., Backlund M., Baran A.G., Nielsen E.I., Speake M., Kuka J., Robinson J., Grinberga S., Robinson L., McDonough M.A., Rydzik A.M., Leissing T.M., Jimenez-Castellanos J.C., Avison M.B., Pinto S. Da Silva, Pannifer A.D., Martjuga M., Widlake E., Priede M., Navratilova I.H., Gniadkowski M., Belfrage A.K., Brandt P., Yli-Kauhaluoma J., Bacque E., Page M.G.P., Bjorkling F., Tyrrell J.M., Spencer J., Lang P.A., Baranczewski P., Canton R., McElroy S.P., Jones P.S., Baquero F., Suna E., Morrison A., Walsh T.R. & Schofield C.J. (2022), Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors, Nature Chemistry 14(1): 15-24.
- Abbasov M.E. Kavanagh M.E., Ichu T.A., Lazear M.R., Tao Y.F., Crowley V.M., Ende C.W..A., Hacker S.M., Ho J., Dix M.M., Suciu R., Hayward M.M., Kiessling L.L. & Cravatt B.F. (2021), A proteome-wide atlas of lysine-reactive chemistry, Nature Chemistry 13(11): 1081-+.
- Chan D.S.-H., Kavanagh M.E., McLean K.J., Munro A.W., Matak-Vinkovic D., Coyne A.G. & Abell C. (2017), Effect of DMSO on protein structure and interactions assessed by collision-induced dissociation and unfolding, Analytical Chemistry 89(18): 9976-9983.
- Kavanagh M.E., Chenge J., Zoufir A., McLean K.J., Coyne A.G., Bender A., Munro A.W. & Abell C. (2017), Fragment profiling approach to inhibitors of the orphan M. tuberculosis P450 CYP144A1, Biochemistry 56(11): 1559-1572.
- Chenge J.T., Le V.D., Swami S., McLean K.J., Kavanagh M.E., Coyne A.G., Rigby S.E.J., Cheesman M.R., Girvan H.M., Levy C.W., Rupp B., von Kries J.P., Abell C., Leys D. & Munro A.W. (2017), Structural characterization and ligand/inhibitor identification provide functional insights into the mycobacterium tuberculosis cytochrome P450 CYP126A1, The Journal of Biological Chemistry 292(4): 1310-1329.
- Davis H.J., Kavanagh M.E., Balan T., Abell C. & Coyne A.G. (2016), Spirooxindoles as novel 3D-fragment scaffolds: synthesis and screening against CYP121 from M. tuberculosis, Bioorganic and Medicinal Chemistry Letters 26(15): 3735-3740.
- Chenge J., Kavanagh M.E., Driscoll M.D., McLean K.J., Young D.B., Cortes T., Matak-Vinkovic D., Levy C.W., Rigby S.E.J., Leys D., Abell C. & Munro A.W. (2016), Structural characterization of CYP144A1-a cytochrome P450 enzyme expressed from alternative transcripts in Mycobacterium tuberculosis, Scientific Reports 6: 26628.
- Kavanagh M.E., Gray J.L., Gilbert S.H., Coyne A.G., McLean K.J., Davis H.J., Munro A.W. & Abell C. (2016), Substrate fragmentation for the design of M.tuberculosis CYP121 inhibitors, ChemMedChem 11(17): 1924-1935.
- Kavanagh M.E., Coyne A.G., McLean K.J., James G.G., Levy C.W., Marino L.B., de Carvalho L.P.S., Chan D.S.H., Hudson S.A., Surade S., Leys D., Munro A.W. & Abell C. (2016), Fragment-based approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors, Journal of Medicinal Chemistry 59(7): 3272-3302.
- Munoz L., Kavanagh M.E., Phoa A.F., Heng B., Dzamko N., Chen E.-J., Doddareddy M.R., Guillemin G.J. & Kassiou M. (2015), Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation, European Journal of Medicinal Chemistry 95: 29-34.
- Reekie T.A., Kavanagh M.E., Longworth M. & Kassiou M. (2013), Synthesis of biologically active seven-membered-ring heterocycles, Synthesis Stuttgart 45(23): 3211-3227.
- Kavanagh M.E., Doddareddy M.R. & Kassiou M. (2013), The development of CNS-active LRRK2 inhibitors using property-directed optimisation, Bioorganic and Medicinal Chemistry Letters 23(13): 3690-3696.